Manager × security

RA CAPITAL MANAGEMENT, L.P. ASND holdings history

ASCENDIS PHARMA A/S · CUSIP 04351P101 · CIK 1346824

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-03-31, RA CAPITAL MANAGEMENT, L.P. reported 10.28M ASND (shares), valued at $2.35B, or 24.92% of its reported non-derivative portfolio. Filed 2026-05-15.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
24.92%
Shares
10.28M
10,281,496
Reported value
$2.35B
USD

Shares unchanged; reported value increased 7.26%, and weight changed +2.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 2026Not reportedNot reported—
Q1 202624.92%10,281,496SEC filing ↗Filed May 15, 2026
Q4 202522.46%10,281,496SEC filing ↗Filed Feb 17, 2026
Q3 202525.19%10,281,496SEC filing ↗Filed Nov 14, 2025
Q2 202529.90%10,281,496SEC filing ↗Filed Aug 14, 2025
Q1 202526.76%10,281,496SEC filing ↗Filed May 15, 2025
Q4 202418.53%10,112,744SEC filing ↗Filed Feb 14, 2025
Q3 202416.72%9,710,428SEC filing ↗Filed Nov 14, 2024
Q2 202418.23%10,108,400SEC filing ↗Filed Aug 14, 2024
Q1 202419.44%10,108,400SEC filing ↗Filed May 15, 2024Amended
Q4 202319.88%10,107,400SEC filing ↗Filed Feb 14, 2024
Q3 202319.76%10,719,555SEC filing ↗Filed Nov 14, 2023Amended

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 202319.76%10,719,555$1.00BThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 202319.88%10,107,400$1.27BShares decreased 5.71%; reported value increased 26.82%, and weight changed +0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 202419.44%10,108,400$1.53BShares increased 0.01%; reported value increased 20.04%, and weight changed -0.44 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 202418.23%10,108,400$1.38BShares unchanged; reported value decreased 9.78%, and weight changed -1.21 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 202416.72%9,710,428$1.45BShares decreased 3.94%; reported value increased 5.17%, and weight changed -1.51 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 202418.53%10,112,744$1.39BShares increased 4.14%; reported value decreased 3.98%, and weight changed +1.81 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 202526.76%10,281,496$1.60BShares increased 1.67%; reported value increased 15.10%, and weight changed +8.23 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 202529.90%10,281,496$1.77BShares unchanged; reported value increased 10.74%, and weight changed +3.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 202525.19%10,281,496$2.04BShares unchanged; reported value increased 15.19%, and weight changed -4.71 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 202522.46%10,281,496$2.19BShares unchanged; reported value increased 7.26%, and weight changed -2.73 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 202624.92%10,281,496$2.35BShares unchanged; reported value increased 7.26%, and weight changed +2.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 2026Not reported——This security is absent from this quarter's filing; a missing record is not treated as zero holdings.—
RA CAPITAL MANAGEMENT, L.P. · ASCENDIS PHARMA A/S

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1346824","quarter":"2026Q2","cusip":"04351P101"}

get_institutional_manager_history
{"cik":"1346824","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.